| Taltz (ixekizumab) / Eli Lilly, Japan Tobacco |
2019-004230-42: Dose reduction of IL17 and IL23 inhibitors for psoriasis Dosis reductie van IL17 en IL23 remmers voor psoriasis |
|
|
| Not yet recruiting | 4 | 244 | Europe | secukinumab, ixekizumab, brodalumab, risankizumab, tildrakizumab, guselkumab, Injection, Cosentyx, Taltz, Kyntheum, Skyrizi, Ilumetri, Tremfya | Radboudumc, ZonMw, KCE | psoriasis psoriasis, psoriasis psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2021-002478-20: IDENTIFICATION OF SYNOVIAL BIOMARKERS OF RESPONSE TO IXEKIZUMAB IN REFRACTORY PSORIATICARTHRITIS IDENTIFICAZIONE DI BIOMARCATORI SINOVIALI DI RISPOSTA AD IXEKIZUMAB NELL’ARTROPATIA PSORIASICA REFRATTARIA: LO STUDIO PRECISE. |
|
|
| Not yet recruiting | 4 | 30 | Europe | TALTZ, [IXEKIZUMAB], Solution for injection in pre-filled syringe, Concentrate for solution for injection, TALTZ | AZIENDA OSPEDALIERO UNIVERSITARIA DI FERRARA, Studio no profit, investigator - initiated in parte finanziato da Ely Lilly, in parte da AOU Ferrara | PSORIATIC ARTHRITIS ARTROPATIA PSORIASICA, PSORIATIC ARTHRITIS ARTRITE PSORIASICA, Diseases [C] - Immune System Diseases [C20] | | | | |
ChiCTR2000034601: Real-world study of ixekizumab (Taltz) in the treatment of psoriasis |
|
|
| Recruiting | 4 | 200 | | Treatment of Taltz | Shanghai Skin Disease Hospital; Shanghai Skin Disease Hospital, raised by researcher | psoriasis | | | | |
| Active, not recruiting | 4 | 244 | Europe | Secukinumab, Cosentyx, Ixekizumab, Taltz, Brodalumab, Kyntheum, Guselkumab, Tremfya, Risankizumab, Skyrizi, Tildrakizumab, Ilumetri, Bimekizumab, Bimzelx | Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Belgium Health Care Knowledge Centre, University Hospital, Ghent | Psoriasis, Psoriasis Vulgaris | 12/25 | 12/25 | | |
| Completed | 4 | 49 | Europe | Venapuncture, Patient questionnaires | University Hospital, Ghent, KU Leuven, University Ghent | Psoriasis Vulgaris | 12/23 | 12/23 | | |
| Recruiting | 4 | 1000 | US | Upadacitinib, Rinvoq, Abatacept, Orencia SQ, Secukinumab, Cosentyx, Tofacitinib, Xeljanz, TNF Inhibitor, Etanercept, Certolizumab, Golimumab SQ, Adalimumab, Canakinumab Injection, Ilaris, Baricitinib, Olumiant, Ixekizumab, Taltz | Jeffrey Curtis, University of Alabama at Birmingham, University of Nebraska, University of Pennsylvania, AbbVie, Bristol-Myers Squibb, Novartis, Eli Lilly and Company, Pfizer, Illumination Health | Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis | 02/24 | 09/24 | | |
NCT05855967: A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India |
|
|
| Completed | 4 | 250 | RoW | Ixekizumab, LY2439821 | Eli Lilly and Company | Plaque Psoriasis, Psoriatic Arthritis | 08/24 | 09/24 | | |
| Not yet recruiting | 4 | 210 | Europe | Proactive TDM-based dosing of secukinumab, Cosentyx, Proactive TDM-based dosing of ixekizumab, Taltz, Proactive TDM-based dosing of guselkumab, Tremfya | University Hospital, Ghent, Belgium Health Care Knowledge Centre | Psoriasis Vulgaris | 03/28 | 03/28 | | |
NCT06085079: Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study |
|
|
| Recruiting | 4 | 20 | US | Ixekizumab Prefilled Syringe | Massachusetts Eye Research and Surgery Institution, Eli Lilly and Company | Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis | 12/24 | 12/24 | | |
ChiCTR2400085840: Evaluation of the Efficacy and Safety of Ixekizumab with and without Methotrexate in the Treatment of Psoriasis |
|
|
| Not yet recruiting | 4 | 128 | | None; None | Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, SHDC2024CRI052 | psoriasis | | | | |
ChiCTR2400087931: Exploration of Precision Individualized Medication Regimen for Psoriasis |
|
|
| Not yet recruiting | 4 | 278 | | Secukinumab Combined with Methotrexate Group; Guselkumab Combined with Methotrexate Group; Tildrakizumab Combined with Methotrexate Group; Ustekinumab Combined with Methotrexate Group; Ixekizumab Combined with Methotrexate Group | Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, the National Key Research and Development Program of China (2023YFC2508103) | Psoriasis is a chronic inflammatory disease mediated by the immune system, influenced by both genetic and environmental factors. Clinically, it manifests as red papules or plaques with white scales. In severe cases, it can present with erythroderma or pustules, accompanied by fever and systemic pain. Besides affecting the skin, it can also cause damage to multiple organs, including nails, joints, | | | | |
NCT04537689: Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis |
|
|
| Recruiting | 4 | 40 | RoW | Ixekizumab, Methotrexate, Cyclosporin A, Acitretin | Singapore General Hospital, Translational Immunology Institute | Plaque Psoriasis | 12/27 | 12/27 | | |
2019-000904-14: A study to assess the efficacy and safety in patients who have been treated for at least 6 months with secukinumab or ixekizumab and have experienced a suboptimal response and then switched to risankizumab. |
|
|
| Not yet recruiting | 3/4 | 250 | Europe | Risankizumab, ABBV-066, Solution for injection in pre-filled syringe | AbbVie, AbbVie Deutschland GmbH & Co.KG, ABBVIE DEUTSCHLAND GMBH & CO. KG, AbbVie Inc | Plaque Psoriasis / Psoriasis Vulgaris, Psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2020-001899-14: An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunosuppressive medication can be tapered without recurrence of symptoms |
|
|
| Not yet recruiting | 3 | 270 | Europe | Prednisolone p.o., Sulfasalazine, Leflunomide, Methotrexate p.o., Methotrexate s.c., Etanercept, Adalimumab, Infliximab, Abatacept s.c., Abatacept i.v., Tablet, Coated tablet, , Solution for injection, Powder for concentrate for solution for infusion, Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe, Solution for injection in dose-dispenser cartridge, Prolonged-release tablet, Xeljanz 5/10mg Filmtabletten, Otezla Filmtabletten, Simponi 50mg Injektionslösung Vorgefüllter Injektor/Fertigspritze, Cimzia 200mg Injektionslösung in einem Fertigpen, Orencia Injektionslösung in einer Fertigspritze, Orencia 250mg Pulver, Cosentyx 150mg Injektionslösung in einer Fertigspritze, Taltz, Cimzia 200mg Injektionslösung in einer Fertigspritze, Cimzia 200mg Injektionslösung in einer Patrone für ein Dosiergerät, Orencia 125mg Injektionslösung im Fertigpen, Cosentyx 150mg Injektionslösung in einem Fertigpen, Stelara 45mg/90mg Injektionslösung, Xeljanz 11mg Retardtablette, Rinvoq 15 mg Retardtablette, Tremfya 100mg Injektionslösung, Skyrizi 75/150mg Injektionslösung | Universitätsklinikum Erlangen, Universitätsklinikum Erlangen | Psoriatic arthritis Psoriasisarthritis, Psoriatic arthritis Gelenkbeteiligung bei Schuppenflechte, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT04527380 / 2018-000681-10: A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis |
|
|
| Active, not recruiting | 3 | 100 | Europe, RoW | Ixekizumab, LY2439821, Adalimumab | Eli Lilly and Company | Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis | 02/24 | 04/28 | | |
TOGETHER-PsA, NCT06588296: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight |
|
|
| Recruiting | 3 | 250 | US | Ixekizumab, LY2439821, Tirzepatide, LY3298176 | Eli Lilly and Company | Psoriatic Arthritis, Obesity | 04/26 | 08/26 | | |
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight |
|
|
| Recruiting | 3 | 250 | US | Ixekizumab, LY2439821, Tirzepatide, LY3298176 | Eli Lilly and Company | Psoriasis, Obesity | 12/25 | 05/26 | | |
NCT04610476: Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis |
|
|
| Recruiting | 3 | 270 | Europe | Prednisolone, Prednisolone generic drugs, Sulfasalazine, Azulfidine, Leflunomide, Arava, Methotrexate, Lantarel, Metex, Tofacitinib, Xeljanz, Apremilast, Otezla, Etanercept, Enbrel, Erelzi, Benepali, Adalimumab, Humira, Amgevita, Imraldi, Hyrimoz, Infliximab, Remicade, Zessly, Inflectra, Certolizumab pegol, Cimzia, Golimumab, Simponi, Abatacept, Orencia, Secukinumab, Cosentyx, Ixekizumab, Taltz, Ustekinumab, Stelara | University of Erlangen-Nürnberg Medical School | Psoriatic Arthritis, Withdrawal, Reduction | 10/24 | 10/25 | | |
NCT06374979: Efficacy and Safety of Ixekizumab in Patients With Refractory Guttate Psoriasis |
|
|
| Not yet recruiting | 2/3 | 50 | NA | Ixekizumab | Second Affiliated Hospital, School of Medicine, Zhejiang University | Guttate Psoriasis | 10/24 | 06/25 | | |
2020-001542-19: Comparing the Efficacy and Safety of Ixekizumab to Placebo in Patients > 6 years of age with EB simplex generalized severe |
|
|
| Not yet recruiting | 2 | 40 | Europe | Taltz 80mg, 3400930060797, Injection, Ixekizumab | CHU NICE, CHU de Nice | Epidermolysis bullosa simplex, Epidermolysis bullosa simplex, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2019-001188-58: The effect of anti-IL17 in new-onset type 1 diabetes: a randomized, double-blind, placebo-controlled trial |
|
|
| Not yet recruiting | 2 | 127 | Europe | Suspension for injection in pre-filled injector, Taltz | Göteborgs Universitet, Eli Lilly Sweden AB, NU Hospital Group, University of Gothenburg | Type 1 diabetes, Type 1 Diabetes, Diseases [C] - Hormonal diseases [C19] | | | | |
| Terminated | 2 | 28 | | | The University of Queensland Diamantina Institute, Eli Lilly Australia Pty Limited | Chronic Venous Ulcers | | | | |
NCT04979910: Targeting IL-17A for Treatment-Resistant Depression |
|
|
| Recruiting | 2 | 20 | US | Ixekizumab | Icahn School of Medicine at Mount Sinai | Major Depressive Disorder | 10/26 | 10/26 | | |
NCT05309616: Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis |
|
|
| Not yet recruiting | 2 | 10 | US | Taltz, Ixekizumab | Yale University, Lilly PharmaceuticalCompany | Idiopathic Subglottic Stenosis | 07/26 | 07/26 | | |
ChiCTR2200059272: A Basket Trial of the Safety and Efficacy of Ixekizumab in Participants with Autoimmune Inflammatory Skin Diseases |
|
|
| Not yet recruiting | 2 | 40 | | Ixekizumab at different doses in adults and juveniles with different body weight ;Ixekizumab at different doses in adults and juveniles with different body weight | Dermatology Hospital of Southern Medical University; Dermatology Hospital of Southern Medical University, Self-funded by the researcher, and sponsored by Eli Lilly Trading Co., Ltd | pityriasis rubra pilaris, hidradenitis suppurativa, Netherton syndrome, erythrokeratodermia variabilis and erythrokeratoderma progressive symmetrica | | | | |
| Recruiting | 2 | 127 | Europe | Ixekizumab, Taltz, Placebo | Göteborg University, Gothia Forum - Center for Clinical Trial, Statistiska Konsultgruppen | Type1 Diabetes Mellitus | 02/27 | 12/27 | | |
NCT05030415: Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris |
|
|
| Completed | 1 | 9 | US | Ixekizumab Auto-Injector | University of New Mexico | Lichen Planus Scalp, Lichen Planus, Lichen Planopilaris | 03/24 | 03/24 | | |
ChiCTR2000030703: A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19) |
|
|
| Recruiting | N/A | 40 | China | Ixekizumab and antiviral therapy ;antiviral therapy | Xiangya Hospital of Central South University; Xiangya Hospital, National project | Novel Coronavirus Pneumonia (COVID-19) | | | | |
ChiCTR2000032847: Chinese Medicine in combination with western medicine for the prevention of relapse in patients with severe psoriasis |
|
|
| Not yet recruiting | N/A | 10 | | oral Chinese herbal medicine (Gu ben hua yu fang) in combination ixekizumab | Guangdong Hospital of traditional Chinese Medicine; Guangdong Provincial Hospital of Chinese Medicine, Clinical research grant funded by Guangdong Provincial Hospital of Chinese Medicine (1010) | Psoriasis | | | | |
NCT05042635: Sequential Treatment of Psoriasis With Traditional Chinese and Western Medicine |
|
|
| Not yet recruiting | N/A | 90 | NA | Ixekizumab+Jueyin Granules, Ixekizumab+Jueyin placebo Granules | Shanghai Yueyang Integrated Medicine Hospital, Shanghai Skin Disease and Venereal Disease Hospital | Plaque Psoriasis | 09/24 | 09/24 | | |
| Recruiting | N/A | 10000 | RoW | Biologic or targeted synthetic DMARD, etanercept, adalimumab, infliximab, golimumab, tocilizumab, abatacept, rituximab, ustekinumab, secukinumab, ixekizumab, or biosimilars, tofacitinib, baricitinib, upadacitinib | Seoul National University Hospital | Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis | 12/29 | 06/30 | | |
ChiCTR2100054950: Chinese medicine in combination with western medicine for the prevention of relapse in patients with severe psoriasis |
|
|
| Recruiting | N/A | 50 | | Guben Qushi Huayu formula granule plus Ixekizumab ;Guben Qushi Huayu formula granule placebo plus Ixekizumab | Guangdong Provincial Hospital of Chinese Medicine; Guangdong Provincial Hospital of Chinese Medicine, Clinical research grant funded by Guangdong Provincial Hospital of Chinese Medicine (1010) | Psoriasis | | | | |
ChiCTR2300077929: A randomized controlled pilot study on the control of psoriasis relapse by dampness-eliminating decoction |
|
|
| Not yet recruiting | N/A | 20 | | Dampness-eliminating decoction follows Ixekizumab; Dampness-eliminating decoction placebo follows Ixekizumab | Guangdong Provincial Hospital of Chinese Medicine; Guangdong Provincial Hospital of Chinese Medicine, none | psoriasis | | | | |
NCT03358693: Molecular Signatures in Inflammatory Skin Disease |
|
|
| Recruiting | N/A | 300 | Europe | Ustekinumab, Infliximab, Secukinumab, Dupilumab, Brodalumab, Ixekizumab, Baricitinib, Abrocitinib, Upadacitinib, Tralokinumab | Prof. Dr. Stephan Weidinger | Atopic Dermatitis, Psoriasis | 12/27 | 12/28 | | |
NCT05503875: Immunoclassification of Psoriasis: a Strategy for Precision Medicine |
|
|
| Recruiting | N/A | 100 | RoW | adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate | Second Affiliated Hospital, School of Medicine, Zhejiang University | Immunoclassification, Psoriasis | 12/27 | 12/27 | | |
ChiCTR2400079786: Effectiveness and safety of Chinese herbal medicine on the control of psoriasis relapse |
|
|
| Not yet recruiting | N/A | 20 | | Dampness-eliminating decoction placebo follows Ixekizumab; Dampness-eliminating decoction follows Ixekizumab | Guangdong Provincial Hospital of Chinese Medicine (Guangdong Provincial Academic of Chinese Medicine Science; Second Clinical Medical College, Guangzhou University of Traditional Chinese Medicine); Guangdong Provincial Hospital of Chinese Medicine (Guangdong Provincial Academic of Chinese Medicine Science; Second Clinical Medical College, Guangzhou University of Traditional Chinese Medicine), none | severe psoriasis vulgaris | | | | |
